AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Fructose-1,6-bisphosphatase isozyme 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O00757

UPID:

F16P2_HUMAN

Alternative names:

D-fructose-1,6-bisphosphate 1-phosphohydrolase 2; Muscle FBPase

Alternative UPACC:

O00757; Q17R39; Q6FI53

Background:

Fructose-1,6-bisphosphatase isozyme 2, also known as Muscle FBPase, plays a pivotal role in carbohydrate metabolism by catalyzing the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. This enzyme is essential for glycogen synthesis from carbohydrate precursors, such as lactate, and operates in the presence of divalent cations.

Therapeutic significance:

The enzyme's link to Leukodystrophy, childhood-onset, remitting, a disorder characterized by loss of developmental abilities and demyelination, underscores its therapeutic significance. Understanding the role of Fructose-1,6-bisphosphatase isozyme 2 could open doors to potential therapeutic strategies for this and related neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.